tbuckley/cabot-search huggingface dataset:
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma
Authors: Emilie Bousquet Mur, Sara Bernardo, Laura Papon, Maicol Mancini, Eric Fabbrizio, Marion Goussard, Irene Ferrer, Anais Giry, Xavier Quantin, Jean-Louis Pujol, Olivier Calvayrac, Herwig P. Moll, Yaël Glasson, Nelly Pirot, Andrei Turtoi, Marta Cañamero, Kwok-Kin Wong, Yosef Yarden, Emilio Casanova, Jean-Charles Soria, Jacques Colinge, Christian W. Siebel, Julien Mazieres, Gilles Favre, Luis Paz-Ares, Antonio Maraver
Journal: Journal of Clinical Investigation (2019)

EGFR-mutated lung adenocarcinoma patients treated with gefitinib and osimertinib show a therapeutic benefit limited by the appearance of secondary mutations, such as EGFRT790M and EGFRC797S. It is generally assumed that these secondary mutations render EGFR completely unresponsive to the inhibitors, but contrary to this, we uncovered here that gefitinib and osimertinib increased STAT3 phosphorylation (p-STAT3) in EGFRT790M and EGFRC797S tumoral cells. Interestingly, we also found that concomitant Notch inhibition with gefitinib or osimertinib treatment induced a p-STAT3-dependent strong reduction in the levels of the transcriptional repressor HES1. Importantly, we showed that tyrosine kinase inhibitor-resistant tumors, with EGFRT790M and EGFRC797S mutations, were highly responsive to the combined treatment of Notch inhibitors with gefitinib or osimertinib, respectively. Finally, in patients with EGFR mutations treated with tyrosine kinase inhibitors, HES1 protein levels increased during relapse and correlated with shorter progression-free survival. Therefore, our results offer a proof of concept for an alternative treatment to chemotherapy in lung adenocarcinoma osimertinib-treated patients after disease progression.
Infection-Related Morbidity Reduced Overall Survival in a Large Real-World Cohort of Transplant Ineligible Newly Diagnosed Myeloma Patients Treated with UK Standard of Care
Authors: Faouzi Djebbari, Fotios Panitsas, Catherine Prodger, Fearn Davies, Kieran Burton, Akhil Khera, Grant Vallance, Sally Moore, Jaimal Kothari, Andy Peniket, Karthik Ramasamy
Journal: Blood (2019)
Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis
Authors: Mudit Dutta, Rahul Mhaskar, Hany Elmariah, Taiga Nishihori, Bijal Shah, Michael Nieder, Lia Perez, Rawan Faramand, Joseph Pidala, Nelli Bejanyan, Farhad Khimani
Journal: Blood (2019)
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Authors: Chi-Chung Li, Brendan Bender, Shen Yin, Zao Li, Cindy Zhang, Genevive Hernandez, Antonia Kwan, Laura Sun, Joanne I Adamkewicz, Hong Wang, Natalie Dimier, Sue-Zen Lim, Carol O'Hear, Laurie H Sehn, Ian W. Flinn, Sung-Soo Yoon, Lihua E Budde, Chunze Li, Michael C Wei
Journal: Blood (2019)
Real-World Outcomes for 205 Danish Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
Authors: Kathrine Aarup, Lisbeth Enggaard, Robert Schou Pedersen, Rasmus Heje Thomsen, Olav Jonas Bergmann, Mikael Frederiksen, Ilse Christiansen, Tine Nielsen, Henrik Frederiksen, Carsten Utoft Niemann, Michael Asger Andersen
Journal: Blood (2019)
Internet based vestibular rehabilitation with and without physiotherapy support for adults aged 50 and older with a chronic vestibular syndrome in general practice: three armed randomised controlled trial
Authors: Vincent A van Vugt, Johannes C van der Wouden, Rosie Essery, Lucy Yardley, Jos W R Twisk, Henriëtte E van der Horst, Otto R Maarsingh
Journal: BMJ (2019)

Abstract Objective To investigate the clinical effectiveness and safety of stand alone and blended internet based vestibular rehabilitation (VR) in the management of chronic vestibular syndromes in general practice. Design Pragmatic, three armed, parallel group, individually randomised controlled trial. Setting 59 general practices in the Netherlands. Participants 322 adults aged 50 and older with a chronic vestibular syndrome. Interventions Stand alone VR comprising a six week, internet based intervention with weekly online sessions and daily exercises (10-20 minutes a day). In the blended VR group, the same internet based intervention was supplemented by face-to-face physiotherapy support (home visits in weeks 1 and 3). Participants in the usual care group received standard care from a general practitioner, without any restrictions. Main outcome measures The primary outcome was vestibular symptoms after six months as measured by the vertigo symptom scale-short form (VSS-SF range 0-60, clinically relevant difference ≥3 points). Secondary outcomes were dizziness related impairment, anxiety, depressive symptoms, subjective improvement of vestibular symptoms after three and six months, and adverse events. Results In the intention-to-treat analysis, participants in the stand alone and blended VR groups had lower VSS-SF scores at six months than participants in the usual care group (adjusted mean difference −4.1 points, 95% confidence interval −5.8 to −2.5; and −3.5 points, −5.1 to −1.9, respectively). Similar differences in VSS-SF scores were seen at three months follow-up. Participants in the stand alone and blended VR groups also experienced less dizziness related impairment, less anxiety, and more subjective improvement of vestibular symptoms at three and six months. No serious adverse events related to online VR occurred during the trial. Conclusion Stand alone and blended internet based VR are clinically effective and safe interventions to treat adults aged 50 and older with a chronic vestibular syndrome. Online VR is an easily accessible form of treatment, with the potential to improve care for an undertreated group of patients in general practice. Trial registration Netherlands Trial Register NTR5712.
STEM-06. TISSUE FACTOR SIGNALING IN GLIOBLASTOMA TUMOR-INITIATING CELLS
Authors: Anh Tran, Dusten Unruh, Snezana Mirkov, Craig Horbinski
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) is an aggressive form of brain cancer with few treatment options, characterized by over-activation of receptor tyrosine kinases (RTKs). Brain tumor-initiating cells (BTICs) is a subpopulation of cells in GBM which have the unique capacity to self-renew, facilitating recurrence. Tissue Factor (TF), normally involved in blood coagulation, is elevated in GBM and strongly correlates with more aggressive behavior. We hypothesize that TF promotes malignant behavior in glioblastoma by activating protease-activated receptor 2 (PAR2), leading to RTK stimulation and the maintenance of brain tumor-initiating cells. Therefore, our approaches are to determine: the mechanisms by which TF-PAR2 stimulates RTK signaling in GBM; the role of RTKs in mediating TF-induced BTIC maintenance in GBM, and the effect of blocking TF signaling on RTK-based therapies against GBM. Our data indicate that TF can activate multiple classes of tumor-promoting RTKs, and sustains cell proliferation through its main receptor, PAR2, even in the presence of an RTK inhibitor. We also found that TF suppression impairs the BTIC phenotype in high TF-expressing, RTK-driven GBM. This project will advance our understanding of how TF promotes malignant behavior, identify a powerful means by which cancers can resist RTK inhibitors currently in clinical use, and demonstrate the therapeutic potential of blocking TF-PAR2 signaling in cancer.
Neutrophils restrain allergic airway inflammation by limiting ILC2 function and monocyte–dendritic cell antigen presentation
Authors: Dhiren F. Patel, Teresa Peiró, Nicoletta Bruno, Juho Vuononvirta, Samia Akthar, Franz Puttur, Chloe J. Pyle, Kornelija Suveizdytė, Simone A. Walker, Aran Singanayagam, Leo M. Carlin, Lisa G. Gregory, Clare M. Lloyd, Robert J. Snelgrove
Journal: Science Immunology (2019)

G-CSF augments T H 2 responses in allergen-sensitized mice and is negatively regulated by transmigrated lung neutrophils.
CBMT-29. PROMOTING FATTY ACID STORAGE BY DIACYLGLYCEROL-ACYLTRANSFERASE 1 PROTECTS GLIOBLASTOMA AGAINST OXIDATIVE STRESS AND MAINTAINS LIPID HOMEOSTASIS FOR RAPID TUMOR GROWTH
Authors: Xiang Cheng, Feng Geng, Yaogang Zhong, Zhihua Tian, Meixia Pan, Chunming Cheng, Craig Horbinski, Xiaokui Mo, Xianlin Han, Deliang Guo
Journal: Neuro-Oncology (2019)

Abstract Fatty acids are essential building blocks and energy substrates of lipids in cells. They constitute the major structural components of membrane lipids, i.e., glycerophospholipids and sphingolipids, and also serve as an important energy resource. Whereas excess fatty acids or dysregulation of fatty acid metabolism causes lipotoxicity, leading to severe cell damage. We previously identified that lipid metabolism is dramatically altered in glioblastoma (GBM), especially fatty acid synthesis, which is greatly elevated in various types of cancers. However, how tumor cells prevent excessive fatty acids accumulation from inducing lipotoxicity has rarely been studied. We recently identified that GBM greatly upregulates diacylglycerol-acyltransferase 1 (DGAT1) to direct excess fatty acids into triglycerides and lipid droplets to prevent oxidative stress. Inhibiting DGAT1 disrupts lipid homeostasis and shifts excessive fatty acids moving into mitochondria for oxidation, resulting in a high level of reactive oxygen species (ROS), mitochondrial damage, cytochrome c release and apoptosis. Inhibiting carnitine palmitoyltransferase to reduce fatty acids shuttling into mitochondria significantly decreases ROS and rescues cell death caused by DGAT1 inhibition. Xenograft models show that genetic or pharmacological inhibition of DGAT1 blocks lipid droplet formation, induces tumor cell apoptosis and markedly suppresses GBM tumor growth. Together, our study demonstrates that DGAT1 upregulation protects GBM from oxidative damage and maintains lipid homeostasis by facilitating excess fatty acids storage. Our data further show that targeting DGAT1 specifically induces lipotoxicity in tumor cells, while sparing normal brain, which is a very promising therapeutic strategy antagonizing GBM and has a high potential to shift current paradigm in treating GBM.
Haploidentical Stem Cell Transplantation with TCR Alpha/Beta and CD19 Depletion in Adult Patients with Hematological Malignancies
Authors: Maria V. Dovydenko, Elena N. Parovichnikova, Larisa A. Kuzmina, Vera A. Vasilyeva, Mikhail Yu. Drokov, Olga M. Koroleva, Ekaterina D. Mikhaltsova, Natalia N. Popova, Zoya V. Konova, Anna A. Dmitrova, Ulyana V. Maslikova, Olga S. Starikova, Tatiana V. Gaponova, Denis V. Kamelskih, Michael Maschan, Valeriy G. Savchenko
Journal: Blood (2019)
<i>GNAI2</i> variants predict nonsteroidal anti‐inflammatory drug hypersensitivity in a genome‐wide study
Authors: Miguel Blanca, Abderrahim Oussalah, José Antonio Cornejo‐García, Natalia Blanca‐López, Rosa‐Maria Guéant‐Rodriguez, Inmaculada Doña, Cristobalina Mayorga, Celine Chery, Pierre Rouyer, Francisco David Carmona, Lara Bossini Castillo, Gabriela Canto, Javier Martin, María José Torres, Jean‐Louis Guéant
Journal: Allergy (2019)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
An International Multi-Center Study To Define the Application of Microarrays in the Diagnosis and Subclassification of Leukemia (MILE Study): Interim Analysis Based on 1,889 Patients Achieves 95.4% Prediction Accuracy.
Authors: Torsten Haferlach, Alexander Kohlmann, Giuseppe Basso, Marie-Christine Bene, James Downing, Sheilla Shurtleff, Jesus M. Hernandez, Wolf-Karsten Hofmann, Thomas J. Kipps, Truus te Kronnie, Wei-Min Liu, Rui Li, Elisabeth Macintyre, Claude Preudhomme, Sabina Chiaretti, Laura Rassenti, John de Vos, Allen Yeoh, Charlotte Brown, Mickey Williams, Ken Mills, Lothar Wieczorek, Robert Foa
Journal: Blood (2006)
STROCSS 2019 Guideline: Strengthening the reporting of cohort studies in surgery
Authors: Riaz Agha, Ali Abdall-Razak, Eleanor Crossley, Naeem Dowlut, Christos Iosifidis, Ginimol Mathew, None Beamishaj, Mohammad Bashashati, Frederick H. Millham, Dennis P. Orgill, Ashraf Noureldin, Iain James Nixon, Abdulrahman Alsawadi, Patrick J. Bradley, Salvatore Giordano, Daniel M. Laskin, Somprakas Basu, Maximilian Johnston, Oliver J. Muensterer, Indraneil Mukherjee, James Chi-Yong Ngu, Michele Valmasoni, Duilio Pagano, Baskaran Vasudevan, Richard David Rosin, James Anthony McCaul, Jörg Albrecht, Jerome R. Hoffman, Mangesh A. Thorat, Samuele Massarut, Achilles Thoma, Boris Kirshtein, Raafat Yahia Afifi, Naheed Farooq, Ben Challacombe, Prathamesh S. Pai, Benjamin Perakath, Huseyin Kadioglu, Jeffrey K. Aronson, Kandiah Raveendran, David Machado-Aranda, Roberto Klappenbach, Donagh Healy, Diana Miguel, Claudio Rodrigues Leles, M. Hammad Ather
Journal: International Journal of Surgery (2019)
Deletion of TLR4 in Townes SS Mice Prevents Microvascular Stasis in Response to Hemin, LPS and Hypoxia/Reoxygenation: Role of Inflammation
Authors: John D Belcher, Fuad Abdulla, Chunsheng Chen, Ping Zhang, Dormarie Rivera-Rodriguez, Rachel Kirchner, Julia Nguyen, Zachary Monroe Kiser, Kristine Nachbor, Jacob Lloyd, Gregory M Vercellotti
Journal: Blood (2019)
Gingival cancer: 11 year follow-up at Karolinska University Hospital (2000-2010).
Authors: Rusana Simonoska
Journal: Journal of Clinical Oncology (2012)

5536 Background: In Sweden, approximately 500-600 cases of oral cancer are diagnosed every year. These include cancer of the gingiva, retromolar trigonum, bucca, hard palate, tongue and floor of the mouth. Each year, around 15 cases of gingival cancer (GC) are diagnosed in the Stockholm region. The goal of this study was to study the onset of symptoms, treatment, prognosis, and sequelae of GC in order to optimize the treatment. Methods: The study consists of a retrospective review of medical records of all diagnosed cases of GC in Stockholm region between 2000-2010, identified through the ENT-clinic Karolinska Hospital patient database. Results: Our retrospective study comprised 156 patients diagnosed with GC. The average age was 72 years sharing equally between the sexes, 50% were smokers. 98% had a squamous cell carcinoma (scc). Presenting symptoms were often lump or ulceration in the gums, pain, bleeding or discomfort/misfit of dentures. Around 30% had premalignant lessons in the oral cavity before diagnosis. 3/4-th of all GC was localized in the lower jaw. 66% of the GC-patients presented as aT4 cancer. At presentation, 26% had a regional metastasis and of those 90% had their primary tumor in the lower jaw. Six cases had bilateral neck disease. 81% of the patients with regional metastasis had low to medium grade of scc differentiation of the primary tumor. 84% of all patients with regional metastasis had a T4 primary tumor. Neck dissection was performed in 38% (n=59). Of these 35 cases where staging neck, i.e. N0 at presentation and in 7 cases (20%) a positive neck disease was found. The risk for second primary was 15%. The overall 5-year survival was 24%. Conclusions: Advanced age and high number of T4 cancer at diagnosis partly explains the poor survival statistics. Almost 30% of the patients in our material have had premalignant lessons in the oral cavity before the cancer diagnosis and are at high risk for new tumors (second primary); therefore patients with GC should be followed up for at least 5 years, possibly longer in the presence of premalignant lessons. GC of the lower jaw is more likely to metastasize than GC of the upper jaw. Due to 20% occult metastasis occurrence in the staging neck cases, we recommend staging neck dissection for patients with GC.
Pretransplant Risk Factors for Calcineurin Inhibitor-Induced Encephalopathy and Limbic Encephalitis Following Allogeneic Hematopoietic Cell Transplantation
Authors: Nao Tanizawa, Hideo Koh, Hiroshi Okamura, Koh Shiro, Satoru Nanno, Mitsutaka Nishimoto, Asao Hirose, Mika Nakamae, Yasuhiro Nakashima, Takahiko Nakane, Masayuki Hino, Hirohisa Nakamae
Journal: Blood (2019)
ASPH-notch Axis guided Exosomal delivery of Prometastatic Secretome renders breast Cancer multi-organ metastasis
Authors: Qiushi Lin, Xuesong Chen, Fanzheng Meng, Kosuke Ogawa, Min Li, Ruipeng Song, Shugeng Zhang, Ziran Zhang, Xianglu Kong, Qinggang Xu, Fuliang He, Xuewei Bai, Bei Sun, Mien-Chie Hung, Lianxin Liu, Jack Wands, Xiaoqun Dong
Journal: Molecular Cancer (2019)

Abstract Background Aspartate β-hydroxylase (ASPH) is silent in normal adult tissues only to re-emerge during oncogenesis where its function is required for generation and maintenance of malignant phenotypes. Exosomes enable prooncogenic secretome delivering and trafficking for long-distance cell-to-cell communication. This study aims to explore molecular mechanisms underlying how ASPH network regulates designated exosomes to program development and progression of breast cancer. Methods Stable cell lines overexpressing or knocking-out of ASPH were established using lentivirus transfection or CRISPR-CAS9 systems. Western blot, MTT, immunofluorescence, luciferase reporter, co-immunoprecipitation, 2D/3-D invasion, tube formation, mammosphere formation, immunohistochemistry and newly developed in vitro metastasis were applied. Results Through physical interactions with Notch receptors, ligands (JAGs) and regulators (ADAM10/17), ASPH activates Notch cascade to provide raw materials (especially MMPs/ADAMs) for synthesis/release of pro-metastatic exosomes. Exosomes orchestrate EMT, 2-D/3-D invasion, stemness, angiogenesis, and premetastatic niche formation. Small molecule inhibitors (SMIs) of ASPH’s β-hydroxylase specifically/efficiently abrogated in vitro metastasis, which mimics basement membrane invasion at primary site, intravasation/extravasation (transendothelial migration), and colonization/outgrowth at distant sites. Multiple organ-metastases in orthotopic and tail vein injection murine models were substantially blocked by a specific SMI. ASPH is silenced in normal adult breast, upregulated from in situ malignancies to highly expressed in invasive/advanced ductal carcinoma. Moderate-high expression of ASPH confers more aggressive molecular subtypes (TNBC or Her2 amplified), early recurrence/progression and devastating outcome (reduced overall/disease-free survival) of breast cancer. Expression profiling of Notch signaling components positively correlates with ASPH expression in breast cancer patients, confirming that ASPH-Notch axis acts functionally in breast tumorigenesis. Conclusions ASPH-Notch axis guides particularly selective exosomes to potentiate multifaceted metastasis. ASPH’s pro-oncogenic/pro-metastatic properties are essential for breast cancer development/progression, revealing a potential target for therapy.
Degradation-regulated architecture of injectable smart hydrogels enhances humoral immune response and potentiates antitumor activity in human lung carcinoma
Authors: Huu Thuy Trang Duong, Thavasyappan Thambi, Yue Yin, Seong Han Kim, Thanh Loc Nguyen, V.H. Giang Phan, Jaeyun Kim, Ji Hoon Jeong, Doo Sung Lee
Journal: Biomaterials (2019)
Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms
Authors: Cody Ashby, Eileen M Boyle, Brian A Walker, Michael A Bauer, Katie Rose Ryan, Judith Dent, Anjan Thakurta, Erin Flynt, Faith E. Davies, Gareth Morgan
Journal: Blood (2019)
Delays in Therapy Do Not Impact Survival in Childhood Acute Lymphoblastic Leukemia: A Report from the Learn Consortium
Authors: Ross Mangum, Tiffany M. Chambers, Andria Stevens, Robert C. Lynch, Evanette Burrows, Tamara P. Miller, Kelly D Getz, Richard Aplenc, Philip J. Lupo, Maria Monica J. Gramatges, Michael E. Scheurer, Karen R. Rabin
Journal: Blood (2019)
The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma
Authors: Tom Knudsen, Brajesh Kumar, Frank Del Greco, Linda Neuman, Howard Levy, Grant E. Blouse
Journal: Blood (2019)
CK2 Inhibitor CX4945 Shows Strong In Vivo Anti Leukemia Effect in AML Via Augmented Ikaros-Mediated Regulation of Global Epigenetic Landscape
Authors: Chandrika Gowda, Chunhua Song, Sadie Steffens, Yali Ding, Bo Zhang, Feng Yue, Soumya Iyer, Pavan kumar Dhanyamraju, Jonathon Payne, Morgann Reed, Kimberly J. Payne, Sinisa Dovat
Journal: Blood (2019)
Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba
Authors: Maria-Victoria Mateos, Saad Z. Usmani, Sebastian Grosicki, Vladimir I. Vorobyev, Ivan Spicka, Vania T.M. Hungria, Sibirina Korenkova, Nizar Bahlis, Max Flogegard, Joan Bladé, Philippe Moreau, Martin F. Kaiser, Shinsuke Iida, Jacob P. Laubach, Tara Masterson, Kristen Anne Lantz, Lisa O'Rourke, Xiang Qin, Dolly A. Parasrampuria, Christoph Heuck, Ming Qi, Hareth Nahi
Journal: Blood (2019)
SURG-08. SURGICAL OUTCOMES OF PITUITARY ADENOMAS TREATED WITH TRANSSPHENOIDAL SURGERY: A SINGLE INSTITUTION’S EXPERIENCE
Authors: Young Beom Seo, Oh-Lyong Kim
Journal: Neuro-Oncology (2019)

Abstract We retrospectively analyzed surgical outcomes of transsphenoidal surgery for pituitary adenomas. A total of 366 consecutive patients undergoing transsphenoidal surgery for a pituitary adenoma from December 1990 through May 2017 were included in this study. The most common tumor type was nonfunctioning pituitary adenoma (NFPA) (63.7%), followed by prolactin-secreting adenoma (20.5%), growth hormone-secreting adenoma (13.4%), adrenocorticotropin-secreting adenoma (2.2%), and thyrotropin-secreting adenoma (0.2%). This cohort study consisted of 164 male and 202 female patients. The median patients age was 48 years. The median follow-up duration was 63 months. Gross-total resection (GTR) was achieved in 83.7% of patients with a NFPA, 76% of prolactin-secreting adenomas, 71.4% of growth hormone-secreting adenomas, 75% of adrenocorticotropin-secreting adenomas, 100% of thyrotropin-secreting adenomas. There were 326 macroadenomas (69.1%). Surgical outcome was better in patients with microadenomas than in patients with macroadenomas (100% and 77.9%, respectively). Improvement of visual disturbances occurred in 148 (93.7%) of the 158 cases. Hormonal impairment by pituitary adenoma was improved in 105 (87.5%) of the 120 cases. There were 24 (8.2%) cases of recurrence after GTR; 17 patients underwent second surgery, 5 patients received radiotherapy, and the others continued conservative treatment. The median time interval between TSA and recurrence was 56 months. Postoperative cerebrospinal fluid leakage occurred in seven (1.9%) of 366 patients. Transsphenoidal surgery is an effective and safe treatment modality for most patients with pituitary adenoma.
A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation
Authors: Jennifer R Brown, Barbara F. Eichhorst, Paolo Ghia, Arnon P. Kater, Jianyong Li, Sudha Khurana, Mostafa Elhamy, Min Hui Wang, John F. Seymour
Journal: Blood (2019)
Statin and COX-2 Inhibitor Exposure Is Associated with Improved Survival in 4913 Newly Diagnosed DLBCL Patients: A Large Population Based Study
Authors: Liam Smyth, Danielle N. Blunt, Evgenia Gatov, Chenthila Nagamuthu, Ruth Croxford, Lee Mozessohn, Matthew Cheung
Journal: Blood (2019)